The HMG-CoA reductase inhibitor rosuvastatin inhibits plasminogen activator inhibitor-1 expression and secretion in human adipocytes

Atherosclerosis

Volumn 196, Issue 2, 2008, Pages 565-573

  Laumen, Helmut ^a   Skurk, Thomas ^a   Hauner, Hans ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Adipocyte; MEKK 1; NF B; PAI 1; Statins

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISOPRENOID; LUCIFERASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; ROSUVASTATIN;

ADIPOCYTE; ADULT; ARTICLE; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG INHIBITION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; REAL TIME POLYMERASE CHAIN REACTION;

3T3-L1 CELLS; ADIPOCYTES; ADULT; ANIMALS; CELLS, CULTURED; DOWN-REGULATION; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LEUPEPTINS; MACROLIDES; MALE; MAP KINASE KINASE KINASE 1; MICE; MIDDLE AGED; NF-KAPPA B; NITRILES; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROMOTER REGIONS (GENETICS); PYRIMIDINES; SIGNAL TRANSDUCTION; SULFONAMIDES; SULFONES; TERPENES; TRANSFECTION;

EID: 38349163794     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2007.06.005     Document Type: Article

References (42)

1. Hill J.O., Wyatt H.R., Reed G.W., and Peters J.C. Obesity and the environment: where do we go from here?. Science 299 (2003) 853-855
2. Alessi M.C., and Juhan-Vague I. PAI-1 and the metabolic syndrome. Links, causes, and consequences. Arterioscler Thromb Vasc Biol 26 (2006) 2200-2207
3. Skurk T., and Hauner H. Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1. Inter J Obes 28 (2004) 1357-1364
4. Lijnen H.R., Maquoi E., Morange P., et al. Nutritionally induced obesity is attenuated in transgenic mice overexpressing plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol 23 (2003) 78-84
5. Ma L.J., Mao S.L., Taylor K.L., et al. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 53 (2004) 336-346
6. Schafer K., Fujisawa K., Konstantinides S., and Loskutoff D.J. Disruption of the plasminogen activator inhibitor 1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice. FASEB J 15 (2001) 1840-1842
7. Dong J., Fujii S., Li H., et al. Interleukin-6 and mevastatin regulate plasminogen activator inhibitor-1 through CCAAT/enhancer-binding protein-{delta}. Arterioscler Thromb Vasc Biol 25 (2005) 1078-1084
8. Kleemann R., and Kooistra T. HMG-CoA reductase inhibitors: effects on chronic subacute inflammation and onset of atherosclerosis induced by dietary cholesterol. Curr Drug Targets Cardiovasc Haematol Disord 5 (2005) 441-453
9. Markle A., and Nicholson A. Pitavastatin alters the expression of thrombotic and fibrinolytic proteins in human vascular cells. J Cell Biochem 90 (2003) 23-32
10. Swiatkowska A., and Cierniewski C. Cerivastatin, a HMG-CoA reductase inhibitor, reduces plasminogen activator inhibitor-1 (PAI-1) expression in endothelial cells by down-regulation of cellular signaling and the inhibition of PAI-1 promoter activity. Jpn J Pharmacol 90 (2002) 337-344
11. van Harmelen V., Skurk T., Rohrig K., and Hauner H. HMG-CoA reductase inhibitor cerivastatin inhibits interleukin-6 expression and secretion in human adipocytes. Horm Metab Res 35 (2003) 466-470
12. Skurk T., Hauner H., and Wabitsch M. Cultures of human adipose precursor cells. Methods Mol Biol 155 (2001) 239-247
13. Aprath-Husmann I., Rohrig H., Gottschling-Zeller H., et al. Effects of leptin on the differentiation and metabolism of human adipocytes. Int J Obes Relat Metab Disord 25 (2001) 1465-1470
14. Wabitsch M., Brenner R., Menge C., et al. Characterization of a human preadipocyte cell strain with high capacity for adipose differentiation. Int J Obes Relat Metab Disord 25 (2001) 8-15
15. Green H., and Meuth M. An established pre-adipose cell line and its differentiation in culture. Cell 3 (1976) 127-133
16. Baumann B., Kistler B., Kirillov A., Bergman Y., and Wirth T. The mutant plasmacytoma cell line S107 allows the identification of distinct pathways leading to NF-kappa B activation. J Biol Chem 273 (1998) 11448-11455
17. Laumen H., Nielsen P., and Wirth T. The BOB.1/OBF. 1 co-activator is essential for octamer-dependent transcription in B cells. Eur J Immunol 30 (2000) 458-469
18. Hou B., Eren M., Painter C.A., et al. Tumor necrosis factor {alpha} activates the human plasminogen activator inhibitor-1 gene through a distal nuclear factor {kappa}B site. J Biol Chem 279 (2004) 18127-18136
19. Takeda K., Ichiki T., Tokunou T., et al. Critical Role of rho-kinase and MEK/ERK pathways for angiotensin II-induced plasminogen activator inhibitor type-1 gene expression. Arterioscler Thromb Vasc Biol 21 (2001) 868-873
20. Chen H.C., and Feener E.P. MEK1,2 response element mediates angiotensin II-stimulated plasminogen activator inhibitor-1 promoter activation. Blood 103 (2004) 2636-2644
21. Aso Y., Wakabayashi S., Yamamoto R., Matsutomo R., Takebayashi K., and Inukai T. Metabolic syndrome accompanied by hypercholesterolemia Is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes: synergistic effects of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor. Diabetes Care 28 (2005) 2211-2216
22. Festa A., Williams K., Tracy R.P., Wagenknecht L.E., and Haffner S.M. Progression of plasminogen activator inhibitor-1 and fibrinogen levels in relation to incident type 2 diabetes. Circulation (2006)
23. Kanaya A.M., Wassel Fyr C., Vittinghoff E., et al. Adipocytokines and incident diabetes mellitus in older adults: the independent effect of plasminogen activator inhibitor 1. Arch Intern Med 166 (2006) 350-356
24. Bourcier T., and Libby P. HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol 20 (2000) 556-562
25. Lopez S., Peiretti F., Bonardo B., Juhan-Vague I., and Nalbone G. Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells. Atherosclerosis 152 (2000) 359-366
26. Morikawa S., Takabe W., Mataki C., et al. The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. J Atheroscler Thromb 9 (2002) 178-183
27. Li J.Q., Zhao S.P., Li Q.Z., et al. Atorvastatin reduces plasminogen activator inhibitor-1 expression in adipose tissue of atherosclerotic rabbits. Clin Chim Acta (2006)
28. Vulin A.I., and Stanley F.M. Oxidative stress activates the plasminogen activator inhibitor type 1 (PAI-1) promoter through an AP-1 response element and cooperates with insulin for additive effects on PAI-1 transcription. J Biol Chem 279 (2004) 25172-25178
29. Landsberger M., Wolff B., Jantzen F., et al. Cerivastatin reduces cytokine-induced surface expression of ICAM-1 via increased shedding in human endothelial cells. Atherosclerosis 190 (2007) 43-52
30. Inoue I., Itoh F., Aoyagi S., et al. Fibrate and statin synergistically increase the transcriptional activities of PPARalpha/RXRalpha and decrease the transactivation of NFkappaB. Biochem Biophys Res Commun 290 (2002) 131-139
31. Hilgendorff A., Muth H., Parviz B., et al. Statins differ in their ability to block NF-kappaB activation in human blood monocytes. Int J Clin Pharmacol Ther 41 (2003) 397-401
32. Madonna R., Di Napoli P., Massaro M., et al. Simvastatin attenuates expression of cytokine-inducible nitric-oxide synthase in embryonic cardiac myoblasts. J Biol Chem 280 (2005) 13503-13511
33. Zelvyte I., Dominaitiene R., Crisby M., and Janciauskiene S. Modulation of inflammatory mediators and PPARgamma and NFkappaB expression by pravastatin in response to lipoproteins in human monocytes in vitro. Pharmacol Res 45 (2002) 147-154
34. Dichtl W., Dulak J., Frick M., et al. HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 23 (2003) 58-63
35. Huwiler A., Xin C., Brust A.K., Briner V.A., and Pfeilschifter J. Differential binding of ceramide to MEKK1 in glomerular endothelial and mesangial cells. Biochim Biophys Acta 1636 (2004) 159-168
36. Kimura M., Soeda S., Oda M., Ochiai T.K.T., Ono N., and Shimeno H. Release of plasminogen activator inhibitor-1 from human astrocytes is regulated by intracellular ceramide. J Neurosci Res 62 (2000) 781-788
37. Chen S., Hu C., Yang D.I., et al. Pravastatin attenuates ceramide-induced cytotoxicity in mouse cerebral endothelial cells with HIF-1 activation and VEGF upregulation. Ann NY Acad Sci 1042 (2005) 357-364
38. Tousoulis D., Antoniades C., Bosinakou E., et al. Effects of atorvastatin on reactive hyperaemia and the thrombosis-fibrinolysis system in patients with heart failure. Heart 91 (2005) 27-31
39. Ludwig S., Dharmalingam S., Erickson-Nesmith S., et al. Impact of simvastatin on hemostatic and fibrinolytic regulators in type 2 diabetes mellitus 1. Diabetes Res Clin Pract 70 (2005) 110-118
40. Eriksson P., Reynisdottir S., Lonnqvist F., Stemme V., Hamsten A., and Arner P. Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals. Diabetologia 41 (1998) 65-71
41. Liao J.K. Isoprenoids as mediators of the biological effects of statins. J Clin Invest 110 (2002) 285-288
42. Kempe S., Kestler H., Lasar A., and Wirth T. NF-kappaB controls the global pro-inflammatory response in endothelial cells: evidence for the regulation of a pro-atherogenic program. Nucleic Acids Res 33 (2005) 5308-5319